Relatively little is known about the influence of extreme body weight on the
pharmacokinetics (PK), pharmacodynamics (PD), efficacy, and safety of drugs used in many …

Background Atrial fibrillation (AF) is an irregular heart rhythm which is becoming more and
more common in this new era. Obesity is a risk factor for cardiovascular events, and obese …

Introduction The clinical outcomes of direct oral anticoagulant (DOAC) dosage regimens in
morbid obesity are uncertain due to limited clinical evidence. This study seeks to bridge this …

Background Guidance for dabigatran and rivaroxaban in overweight patients diagnosed
with non-valvular atrial fibrillation (NVAF) is still lacking. Aim Compare the effectiveness and …

Background: A novel risk prediction model appears to be urgently required to improve the
assessment of thrombotic risk in overweight patients with nonvalvular atrial fibrillation …

Objective Through predictable pharmacokinetics—including a convenient fixed-dose
regimen, direct oral anticoagulants (DOACs) are preferred over previous treatments in …

Background and aims The association between body mass index (BMI) and clinical
outcomes of patients with non-valvular atrial fibrillation (NVAF) taking oral anticoagulants …

Background Despite data derived from observational studies, optimal anticoagulation
strategies have yet to be established for patients with nonvalvular atrial fibrillation and …

Objective: The objective of the study was to discuss the controversies surrounding the use
and dosing of direct-acting oral anticoagulants (DOACs) in obese patients recognizing the …

Background: A novel risk prediction model appears to be urgently required to improve the
assessment of thrombotic risk in overweight patients with nonvalvular atrial fibrillation …